{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:03:02Z","timestamp":1791385382088,"version":"4.3.3"},"reference-count":46,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) poses significant therapeutic challenges due to the limited availability of targeted treatment options and the development of resistance to chemotherapy, including doxorubicin (DOX). The objective of this study was to investigate the impact of inhibiting activated pathways in DOX-resistant TNBC and examine the effects on MAPK and PI3K\/Akt signaling pathways, cell cycle regulation, and the regulators of the epithelial\u2013mesenchymal transition (EMT) process. Continuous exposure of cells to increasing concentrations of DOX resulted in the selection of resistant cells that exhibited EMT characteristics. We assessed the expression levels of markers related to cell death, survival, mitophagy pathways and EMT using Western blotting and qPCR in both sensitive and resistant cells with activated-pathway inhibitor treatments. Additionally, we demonstrated differences in migration capacity between resistant and sensitive cells with or without inhibitor treatments. It was found that MEK inhibition was less effective than PI3K inhibition in both sensitive and resistant cells. Expression analyses clearly demonstrated that resistant cells exhibited more aggressive behavior, as indicated by EMT- and survival-related gene expressions. The combination of MEK and PI3K inhibitors was more effective in shutting down these signals in both cell types. The ability to induce EMT in DOX-resistant cells revealed that one form of resistance might combine with another, acting as a mediator for cellular switch. Although drug resistance and various inhibitors reduce the proliferative capacity of cells and related parameters, resistance contributes to the acquisition of metastatic characteristics.<\/jats:p>","DOI":"10.3390\/ijms27062792","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:50:36Z","timestamp":1773921036000},"page":"2792","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting Activated Pathways in Doxorubicin-Resistant TNBC Alters Signaling, Survival and EMT: A Double-Edged Sword"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-3538","authenticated-orcid":false,"given":"Irem","family":"Dogan Turacli","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Department of Medical Biology, Ufuk University, Ankara 06520, Turkey"},{"name":"Ogretmen Naime Tomek Research Laboratory (ONTAL), Faculty of Medicine, Ufuk University, Ankara 06520, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-4532","authenticated-orcid":false,"given":"Sahika","family":"Cingir Koker","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Medical Biology, Ufuk University, Ankara 06520, Turkey"},{"name":"Ogretmen Naime Tomek Research Laboratory (ONTAL), Faculty of Medicine, Ufuk University, Ankara 06520, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kubra","family":"Paspal Eroglu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Medical Biology, Ufuk University, Ankara 06520, Turkey"},{"name":"Ogretmen Naime Tomek Research Laboratory (ONTAL), Faculty of Medicine, Ufuk University, Ankara 06520, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banu","family":"Yalcin","sequence":"additional","affiliation":[{"name":"Ogretmen Naime Tomek Research Laboratory (ONTAL), Faculty of Medicine, Ufuk University, Ankara 06520, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"955","DOI":"10.4161\/cbt.10.10.13879","article-title":"Histological, molecular and functional subtypes of breast cancers","volume":"10","author":"Malhotra","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-1293-1","article-title":"Triple negative breast cancer: Unmet medical needs","volume":"125","author":"Pal","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s13346-018-0551-3","article-title":"Metastatic and triple-negative breast cancer: Challenges and treatment options","volume":"8","author":"Sapiezynski","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11795549221099869","DOI":"10.1177\/11795549221099869","article-title":"Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges","volume":"16","author":"Uchimiak","year":"2022","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., and Depil, S. (2019). Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00168"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/cells12040659","article-title":"Doxorubicin\u2014An Agent with Multiple Mechanisms of Anticancer Activity","volume":"12","author":"Kciuk","year":"2023","journal-title":"Cells"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"C195","DOI":"10.1152\/ajpcell.00217.2011","article-title":"Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes","volume":"302","author":"Gilliam","year":"2012","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s12282-024-01553-x","article-title":"The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer","volume":"31","author":"Ye","year":"2024","journal-title":"Breast Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.drudis.2021.09.020","article-title":"Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects","volume":"27","author":"Mirzaei","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Christowitz, C., Davis, T., Isaacs, A., van Niekerk, G., Hattingh, S., and Engelbrecht, A.-M. (2019). Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5939-z"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1038\/onc.2012.491","article-title":"The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment","volume":"32","author":"Monteiro","year":"2013","journal-title":"Oncogene"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/cells8090957","article-title":"Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge","volume":"8","author":"Nedeljkovic","year":"2019","journal-title":"Cells"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1368-7646(02)00120-6","article-title":"Activation of the PI3K\/Akt pathway and chemotherapeutic resistance","volume":"5","author":"West","year":"2002","journal-title":"Drug Resist. Updat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/annonc\/mdz133","article-title":"Targeting the PI3-kinase pathway in triple-negative breast cancer","volume":"30","author":"Pascual","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tox.2010.03.012","article-title":"Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells","volume":"271","author":"Kahl","year":"2010","journal-title":"Toxicology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: Origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Qian, S., Wei, Z., Yang, W., Huang, J., Yang, Y., and Wang, J. (2022). The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.985363"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ravizza, R., Gariboldi, M.B., Passarelli, L., and Monti, E. (2004). Role of the p53\/p21 system in the response of human colon carcinoma cells to Doxorubicin. BMC Cancer, 4.","DOI":"10.1186\/1471-2407-4-92"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"174344","DOI":"10.1016\/j.ejphar.2021.174344","article-title":"The involvement of epithelial-to-mesenchymal transition in doxorubicin resistance: Possible molecular targets","volume":"908","author":"Mirzaei","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11010-017-3059-0","article-title":"SOSTDC1 inhibits follicular thyroid cancer cell proliferation, migration, and EMT via suppressing PI3K\/Akt and MAPK\/Erk signaling pathways","volume":"435","author":"Zhou","year":"2017","journal-title":"Mol. Cell. Biochem."},{"key":"ref_22","first-page":"617","article-title":"Dual Role of Mitophagy in Cancer Drug Resistance","volume":"38","author":"Yan","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zhang, H., Xie, S., and Deng, W. (2024). Mitophagy in Doxorubicin-Induced Cardiotoxicity: Insights into Molecular Biology and Novel Therapeutic Strategies. Biomolecules, 14.","DOI":"10.3390\/biom14121614"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/cdd.2012.81","article-title":"The pathways of mitophagy for quality control and clearance of mitochondria","volume":"20","author":"Ashrafi","year":"2013","journal-title":"Cell Death Differ."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1016\/j.molcel.2023.08.021","article-title":"Mitochondrial degradation: Mitophagy and beyond","volume":"83","author":"Uoselis","year":"2023","journal-title":"Mol. Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1007\/s00018-021-03774-1","article-title":"Mitophagy in tumorigenesis and metastasis","volume":"78","author":"Poole","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41419-021-04469-y","article-title":"BNIP3L\/NIX-mediated mitophagy: Molecular mechanisms and implications for human disease","volume":"13","author":"Li","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: Pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"npj Breast Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"15182","DOI":"10.1073\/pnas.1922072117","article-title":"Uncoupling DNA damage from chromatin damage to detoxify doxorubicin","volume":"117","author":"Qiao","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7471","DOI":"10.1158\/1078-0432.CCR-09-1070","article-title":"Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology","volume":"15","author":"Ellis","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Bou Antoun, N., and Chioni, A.M. (2023). Dysregulated Signalling Pathways Driving Anticancer Drug Resistance. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202307.1284.v1"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"109979","DOI":"10.1016\/j.isci.2024.109979","article-title":"Hallmarks of cancer resistance","volume":"27","author":"Tufail","year":"2024","journal-title":"iScience"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s10565-024-09980-4","article-title":"Molecular mechanism of ZC3H13-mediated ferroptosis in doxorubicin resistance of triple negative breast cancer","volume":"41","author":"Huang","year":"2025","journal-title":"Cell Biol. Toxicol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13058-024-01799-5","article-title":"Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin\/OKI-179 to promote apoptosis","volume":"26","author":"Smoots","year":"2024","journal-title":"Breast Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41419-022-04783-z","article-title":"Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Paramanantham, A., Jung, E.J., Kim, H.J., Jeong, B.K., Jung, J.-M., Kim, G.S., Hong, S.C., and Lee, W.S. (2021). Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through Autocrine Signaling. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212438"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41698-024-00780-x","article-title":"HuR inhibition overcomes cFLIP-mediated doxorubicin resistance in triple-negative breast cancer","volume":"8","author":"Wei","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/1878-0261.12102","article-title":"MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701","volume":"11","author":"Chen","year":"2017","journal-title":"Mol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41467-019-09898-0","article-title":"MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer","volume":"10","author":"Zhan","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"43013","DOI":"10.1038\/srep43013","article-title":"PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer","volume":"7","author":"Milella","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"102137","DOI":"10.1016\/j.ctrv.2020.102137","article-title":"MEK inhibitor resistance mechanisms and recent developments in combination trials","volume":"92","author":"Kun","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"Joyce","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.canlet.2016.11.018","article-title":"Doxorubicin-induced mitophagy contributes to drug resistance in cancer stem cells from HCT8 human colorectal cancer cells","volume":"388","author":"Yan","year":"2017","journal-title":"Cancer Lett."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/6\/2792\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:52:30Z","timestamp":1773921150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/6\/2792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijms27062792"],"URL":"https:\/\/doi.org\/10.3390\/ijms27062792","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]}}}